SCHEDULE: Stone & RK Stone Miami Boost Scinai Immunotherapeutics Stake

Daniel E. Stone and RK Stone Miami, LLC collectively report a 16.61% beneficial ownership stake in Scinai Immunotherapeutics Ltd. ADSs.

Summary

• Daniel E. Stone and RK Stone Miami, LLC, as a group, beneficially own an aggregate of 584,534 American Depositary Shares (ADSs) of Scinai Immunotherapeutics Ltd.
• This aggregate ownership represents 16.61% of the class of securities outstanding.
• Daniel E. Stone individually holds sole voting and dispositive power over 346,667 ADSs, equating to 9.9% of the class.
• RK Stone Miami, LLC individually holds sole voting and dispositive power over 237,867 ADSs, equating to 6.71% of the class.
• The beneficial ownership percentages are calculated based on 13,872,899,584 ordinary shares outstanding as of December 31, 2025.
• RK Stone Miami, LLC exercised 200,000 warrants on September 22, 2025.
• As of December 31, 2025, RK Stone Miami, LLC holds 200,000 ADSs and 283,426 ADS pre-funded warrants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive, as a significant beneficial ownership stake of 16.61% by a sophisticated investor group suggests confidence in the company, despite the passive nature of a 13G filing.

Positives

• A significant aggregate beneficial ownership of 16.61% by Daniel E. Stone and RK Stone Miami, LLC indicates strong conviction in Scinai Immunotherapeutics Ltd.
• The exercise of 200,000 warrants by RK Stone Miami, LLC on September 22, 2025, demonstrates active investment and commitment.

Risks

• RK Stone Miami, LLC's ability to exercise its 283,426 ADS pre-funded warrants is limited by a beneficial ownership cap of 9.99% of ordinary shares, which could restrict full realization of potential upside from these warrants.
• Future issuances of ordinary shares or ADSs by Scinai Immunotherapeutics Ltd. to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable, potentially leading to dilution for existing shareholders if not managed carefully, although the filing states it would not increase the reporting person's beneficial ownership percentage.

Future Outlook

RK Stone Miami, LLC holds 283,426 ADS pre-funded warrants, which are subject to a 9.99% beneficial ownership limitation. Future issuances of ordinary shares or ADSs by Scinai Immunotherapeutics Ltd. to third parties are expected to enable the exercisability of additional amounts of these pre-funded warrants within the existing limitation, without increasing the reporting person's beneficial ownership percentage.

Management Comments

• Daniel E. Stone certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant beneficial ownership stake, such as the 16.61% reported by Daniel E. Stone and RK Stone Miami, LLC in Scinai Immunotherapeutics, can signal confidence from institutional or sophisticated investors in the company's long-term prospects within the biotechnology or immunotherapeutics sector. Such a substantial holding could also provide a degree of stability to the shareholder base, although the specific intentions beyond passive investment are limited by the 13G filing type.

Comparison to Industry Standards

• NA This filing primarily concerns beneficial ownership disclosure by an investor group, not the operational or financial performance of Scinai Immunotherapeutics Ltd. Therefore, direct comparisons to industry-standard operational benchmarks or competitor results are not applicable based on the content of this document.

Stakeholder Impact

• Shareholders: The significant stake held by Daniel E. Stone and RK Stone Miami, LLC could be viewed positively, signaling investor confidence. However, future equity issuances by the company, as mentioned in the filing, could lead to dilution.
• Company Management: The certification that the securities are not held for influencing control (beyond potential nominations) suggests a generally passive, but significant, shareholder presence.

Next Steps

• RK Stone Miami, LLC holds 283,426 ADS pre-funded warrants, which may become exercisable in additional amounts upon future issuances of ordinary shares or ADSs by the issuer to third parties, subject to a 9.99% beneficial ownership limitation.

Key Dates

Recommendation

The filing indicates a significant and sustained interest from a major investor group, which is generally a positive signal. However, as a Schedule 13G, it primarily discloses ownership and does not provide new operational or financial performance data for Scinai Immunotherapeutics Ltd. The mention of future equity issuances and warrant exercisability introduces potential dilution, balancing the positive signal of investor confidence. Therefore, a 'hold' recommendation is appropriate, awaiting further operational updates or strategic developments from the company itself.

Keywords

Scinai Immunotherapeutics, ADS, American Depositary Shares, Schedule 13G, Beneficial Ownership, Daniel E. Stone, RK Stone Miami, Warrants, Immunotherapeutics, Biopharma